GPD1L Antibody (N-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8N335 |
---|---|
Clone Names | 91013045 |
Gene ID | 23171 |
---|---|
Other Names | Glycerol-3-phosphate dehydrogenase 1-like protein, GPD1-L, GPD1L, KIAA0089 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | GPD1L (HGNC:28956) |
---|---|
Synonyms | KIAA0089 |
Function | Plays a role in regulating cardiac sodium current; decreased enzymatic activity with resulting increased levels of glycerol 3- phosphate activating the DPD1L-dependent SCN5A phosphorylation pathway, may ultimately lead to decreased sodium current; cardiac sodium current may also be reduced due to alterations of NAD(H) balance induced by DPD1L. |
Cellular Location | Cytoplasm. Note=Localized to the region of the plasma membrane |
Tissue Location | Most highly expressed in heart tissue, with lower levels in the skeletal muscle, kidney, lung and other organs |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene catalyzes the conversionof sn-glycerol 3-phosphate to glycerone phosphate. The encodedprotein is found in the cytoplasm, associated with the plasmamembrane, where it binds the sodium channel, voltage-gated, type V,alpha subunit (SCN5A). Defects in this gene are a cause of Brugadasyndrome type 2 (BRS2) as well as sudden infant death syndrome(SIDS).
References
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Liu, M., et al. Circ. Res. 105(8):737-745(2009)Valdivia, C.R., et al. Am. J. Physiol. Heart Circ. Physiol. 297 (4), H1446-H1452 (2009) :Makiyama, T., et al. Circ. J. 72(10):1705-1706(2008)London, B., et al. Circulation 116(20):2260-2268(2007)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.